NCT04746235View on ClinicalTrials.gov

Venetoclax and ASTX727 for the Treatment of Relapsed, Refractory, or Newly Diagnosed Acute Myeloid Leukemia

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

85

Participants

Timeline

Start Date

February 22, 2021

Primary Completion Date

October 31, 2026

Study Completion Date

October 31, 2026

Conditions
Acute Myeloid LeukemiaRecurrent Acute Myeloid LeukemiaRefractory Acute Myeloid Leukemia
Interventions
DRUG

Decitabine and Cedazuridine

Given PO

DRUG

Venetoclax

Given PO

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
lead

M.D. Anderson Cancer Center

OTHER